• Explore /
  • Poster
  • / Implementing fragmentomics into real world screening interventions to evaluate clinical utility among individuals with elevated risk for lung cancer (FIRSTLUNG) L301.

Implementing fragmentomics into real world screening interventions to evaluate clinical utility among individuals with elevated risk for lung cancer (FIRSTLUNG) L301.

Abstract Poster

Authors

Lindsey Cotton

Lindsey Behlen Cotton

DELFI Diagnostics, Baltimore, MD

Lindsey Behlen Cotton , Chris Cisar , Peter Brian Bach , Carolina Sheridan , Niti U. Trivedi , James Davis , Demetria Tennefoss

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Quality Care/Health Services Research

Track

Care Delivery and Quality Care

Sub Track

Real-World Data/Outcomes

Clinical Trial Registration Number

NCT06145750

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS11189)

DOI

10.1200/JCO.2024.42.16_suppl.TPS11189

Abstract #

TPS11189

Poster Bd #

383b

Abstract Disclosures

Similar Posters

First Author: Nehemias Antonio Guevara Rodriguez

First Author: Jesilyn Palec

First Author: Abdul Zakkar

First Author: Kyle Austin Sugg